The Danish National Multiple Myeloma Registry

Figures & data

Figure 1 Age-dependent overall survival of 2,907 newly diagnosed Danish patients with symptomatic multiple myeloma.

Notes: The patients were registered in the Danish National Multiple Myeloma Registry between January 1, 2005, and June 30, 2015. Median follow-up is 59.5 months. The completeness of the registry is ~100%, and the survival curves therefore present “real life data” on multiple myeloma survival in the whole population.

Table 1 Main registered baseline parameters at diagnosis in multiple myeloma, smoldering MM, plasma cell leukemia, and solitary plasmacytoma in the Danish National Multiple Myeloma Registry

Patient related	Myeloma clonal characteristics	Myeloma complications	Prognostical parameters
Age Sex Personal identification number Postal code Date of diagnosis	M-component subtype S-M-component concentration U-M-component concentration Light-chain subtype S-free light kappa lambda chain concentration and ratio Bone marrow plasma cell infiltration (%) Cytogenetics Karyotype FISH abnormalities	Paraclinical findings  Bone disease by skeletal survey  CT/MRI/PET/DEXA (if performed)  Calcium  Creatinine  Hemoglobin  Leukocyte count  Thrombocyte count  U-protein Clinical complications  Medullary compression  Bone fractures  Hemodialysis-dependent renal failure  Amyloidosis  Polyneuropathy	ISS Beta-2-microglobulin Albumin WHO performance status LDH CRP

Abbreviations: CRP, C-reactive protein; CT, computed tomography; DEXA, dual-energy X-ray absorptiometry; FISH, fluorescence in situ hybridization; ISS, International Staging System; LDH, lactate dehydrogenase; MM, multiple myeloma; MRI, magnetic resonance imaging; PET, positron emission tomography; WHO, World Health Organization.

Table 2 Main registered parameters concerning treatment, response to treatment and course of disease in multiple myeloma, plasma cell leukemia, and solitary plasmacytoma in the Danish National Multiple Myeloma Registry

At diagnosis	First-line treatment	Second-line treatment	Follow-up
Planned antimyeloma regimen Planned radiotherapy Planned bisphosphonates	Received first-line treatment regimen Date for start and end of treatment Best response according to IMWG criteria	Date of disease progression after first-line therapy (PFS1) Type of progression Received second-line treatment regimen Date for start and end of second-line treatment Best response according to IMWG criteria	Disease status Number of lines of treatment regimens Date of death Cause of death

Abbreviations: IMWG, International Myeloma Working Group; PFS1, first progression-free survival.